Contemporary management of generalized myasthenia gravis (gMG) is complicated by heterogeneous patient presentation, by intermittent periods of disease remission and exacerbation, and by substantial adverse impact on quality of life for affected patients and their families/caretakers. Recent therapeutic advances in the management of gMG include specific targeting of the neonatal Fc receptor (FcRn) and complement component 5.  These new approaches have shown promising results in allowing appropriately selected patients to reduce their long-term steroid doses. Administration of some new therapies is becoming less onerous with self-injection of subcutaneous medicines, prefilled syringes for dosing accuracy, and associated increased patient convenience and lower costs of care. These advances open new opportunities for HCPs to individualized treatment regimens, to facilitate shared decision-making discussions, and to overcome treatment resistance and/or refractory disease. In this joint accredited program, expert neuromuscular specialists Drs. Neelam Goyal, Tuan Vu, and Ali Habib will offer an update on nonsteroidal therapies for gMG and newer options for increasing self-management opportunities that empower patients and improve clinical and quality-of-life outcomes for patients.